<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062590</url>
  </required_header>
  <id_info>
    <org_study_id>2022-616</org_study_id>
    <nct_id>NCT05062590</nct_id>
  </id_info>
  <brief_title>Evolution and Adaptation to Caregiver of a Socio-geriatric Evaluation</brief_title>
  <acronym>ESOGER</acronym>
  <official_title>Socio-geriatric Evaluation (ESOGER): A Clinical Tool in Telehealth to Fight Against Vulnerable Seniors's Health Alterations and Social Isolation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the COVID-19 pandemic, elderly people (EP) living at home have seen their health&#xD;
      deteriorated, thus increasing their needs in support and care. Indeed, while it was estimated&#xD;
      that before the pandemic120 000 unattended living at home EP required care and services&#xD;
      (taking bath, access to medication and food, etc.), the number doubled after COVID-19.&#xD;
      Therefore, the waiting list for socio-medical services for unattended vulnerable clientele&#xD;
      without a family doctor grew from 1300 à 1715 EP in a couple of months during the pandemic.&#xD;
      With these numbers, it becomes clear that an intervention is needed. Truly, the Institut&#xD;
      National d'Excellence en Santé et Services Sociaux (INESSS) conclude that it was pivotal to&#xD;
      first identify the most vulnerable EP and second re-orient them according to their needs.&#xD;
      Thus the investigator developed the Évaluation et orientation SOcio-GÉRiatrique (ESOGER)&#xD;
      questionnaire available on a secure digital plateform enabling both a rapid evaluation and&#xD;
      intervention to asses EP needs and provide the adequate ressources. Investigator's previous&#xD;
      research has demonstrated that ESOGER is one of the rare clinical tools of first contact in&#xD;
      telehealth while being global, multidimensional, and equitable. For this study, the&#xD;
      investigator aims to evaluate the effect of ESOGER on EP physical and mental health, loss of&#xD;
      autonomy, social isolation, quality of life and ressources consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>presence or not of fever, cough, and shortness of breath (binary question)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>psychological fraility</measure>
    <time_frame>3 months</time_frame>
    <description>Anxiety verbal analogic scale, score from 0= no anxiety to 10= extremly anxious</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Social health</measure>
    <time_frame>3 months</time_frame>
    <description>Issues related to medication and food delivery and access to home care. Presence or not of a shortage in food, medication and home care ( binary question)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Socio-economic characteristics</measure>
    <time_frame>3 months</time_frame>
    <description>Presence or not of socio-economic problems (binary questions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant's Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by the EQ-5D scale with two parts, scale 1 score from 1= no problem to 5 ( sever health problems) and scale 2 visual analogic scale score from 0= worst possible health to 100= best possible health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Autonomy</measure>
    <time_frame>3 months</time_frame>
    <description>ADL scale score from 0= very dependent to 6= very independent and IADL scale score 0= not autonomous 4= autonomous.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caregiver burden</measure>
    <time_frame>3 months</time_frame>
    <description>Based on Zarit scale, score from 0= no burden to 16= high caregiver burnder</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Social Isolation</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Group Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recommendations</intervention_name>
    <description>Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP</description>
    <arm_group_label>Group Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 65 and more&#xD;
&#xD;
          -  Living at home on the territory CIUSSS-Centre-Sud de l'île-de-Montréal (CCSMTL) of&#xD;
             Jeanne-Mance&#xD;
&#xD;
          -  Brief Geriatric Assessment (BGA) score of 1/14 or more defining a severly to milidly&#xD;
             frail health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Principal address outside of the CCSMTL's Jeanne-Mance territory&#xD;
&#xD;
          -  Participate at another clinical trial, to avoid interferences&#xD;
&#xD;
          -  Not understand written or spoken French or English, questionnaires are only available&#xD;
             in French and English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Beauchet, MD</last_name>
    <phone>514-340-3540</phone>
    <phone_ext>3637</phone_ext>
    <email>olivier.beauchet@umontreal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRIUGM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3W 1W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Kévin Galéry</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal</investigator_affiliation>
    <investigator_full_name>Olivier Beauchet</investigator_full_name>
    <investigator_title>MD, PhD, Senior researcher, Director of laboratory</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

